Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;34(1):e14404.
doi: 10.1111/dth.14404. Epub 2020 Oct 20.

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

Tamara Searle  1 , Faisal R Ali  2   3 , Firas Al-Niaimi  2   4
Affiliations
Review

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

Tamara Searle et al. Dermatol Ther. 2021 Jan.

Abstract

Intralesional methotrexate (IL-MTX) is a long-established treatment, which is arguably underutilized by dermatologists. We describe the underlying evidence base and practical considerations for its broad range of cutaneous indications, including in cutaneous oncology (keratoacanthomas, squamous cell carcinomas, lymphomas), inflammatory dermatology (nail psoriasis, plaque psoriasis, pyoderma gangrenosum, cutaneous Crohn's disease, amyloidosis), cutaneous infections (viral warts) and for treatment of filler complications. In certain circumstances, IL-MTX can be more efficacious and less invasive than other treatments, with fewer adverse effects. Dermatologists should consider using IL-MTX for a range of recalcitrant cutaneous conditions, particularly for those patients not amenable to surgery or systemic therapy.

Keywords: Intralesional; Keratoacanthoma; methotrexate; squamous cell carcinoma; warts.

PubMed Disclaimer

References

REFERENCES

    1. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64(2):413-422.
    1. Bonerandi JJ, Beauvillain C, Caquant L, et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol. 2011;25:1-51.
    1. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991;25:306-318.
    1. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41:36-51.
    1. Yokoi I, Ishikawa E, Koura A, et al. Successful treatment of primary cutaneous anaplastic large cell lymphoma with intralesional methotrexate therapy. Acta Derm-Venereol. May 1, 2014;94(3):319-320.

LinkOut - more resources